A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–55
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Female individuals not of childbearing potential (INOCBP) and males.
Healthy as determined by medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory assessments.
Body mass index (BMI) 18.0 to 32.0 kg/m2 , inclusive, for Parts A and B.
You may not be if
Any significant acute or chronic medical illness as determined by the investigator.
History of clinically relevant cardiac disease as determined by the investigator, symptomatic or asymptomatic arrhythmias, presyncope or syncopal episodes, or additional risk factors for ventricular arrhythmias.
Any significant history of disease of the cardiovascular system that in the opinion of the Investigator makes the participant unsuitable for enrollment into the study.
Clareo Health | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants
